NCT07236203 Predictive Factors for the Efficacy of CD19 CAR-T Therapy in Relapsed/Refractory Large B-Cell Lymphoma: A Clinical Study
| NCT ID | NCT07236203 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Fudan University |
| Condition | Large B-Cell Lymphoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 80 participants |
| Start Date | 2024-02-29 |
| Primary Completion | 2026-08-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 80 participants in total. It began in 2024-02-29 with a primary completion date of 2026-08-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a single-center real-world study aiming to explore predictive factors for the efficacy of CAR-T therapy in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).
Eligibility Criteria
Inclusion Criteria: 1. Pathological diagnosis confirmed as large B-cell lymphoma 2. Patients with relapsed or refractory large B-cell lymphoma (R/R DLBCL) after receiving second-line or above systemic treatment 3. Intend to use CAR-T products approved by NMPA for the treatment of R/R LBCL. 4. Understand and voluntarily sign a written informed consent form. For patients without full civil capacity, their guardians must be informed and sign the corresponding informed consent form and note the date, as for the patient himself, informed consent may be obtained based on the specific circumstances. Exclusion Criteria: 1. Poor patient compliance 2. During pregnancy or lactation 3. After judgment by the researcher, the patient has other unsuitable conditions for inclusion in the study.
Contact & Investigator
Chuan xu Liu, M.D
PRINCIPAL INVESTIGATOR
Fudan University
Frequently Asked Questions
Who can join the NCT07236203 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Large B-Cell Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07236203 currently recruiting?
Yes, NCT07236203 is actively recruiting participants. Contact the research team at liuchuanxu@shca.org.cn for enrollment information.
Where is the NCT07236203 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07236203 clinical trial?
NCT07236203 is sponsored by Fudan University. The principal investigator is Chuan xu Liu, M.D at Fudan University. The trial plans to enroll 80 participants.